Trove
Sign In Sign Up

Michael Cella

Person
Mentions
186
Relationships
12
Events
1
Documents
89
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.

Event Timeline

Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.
12 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
person Cowen
Employee
18 Very Strong
38
View
person Cowen
Employment affiliation
11 Very Strong
19
View
person Cowen
Professional
7
3
View
person Cowen
Employment internal distribution
7
2
View
person Cowen
Employment internal
6
2
View
person Cowen
Client
6
1
View
person Cowen
Professional employment
6
2
View
person Cowen
Employment
5
1
View
person Cowen and Company
Employment affiliation
5
1
View
person Cowen and Company, LLC
Employee
5
1
View
person Cowen
Employment recipient
5
1
View
person Cowen and Company
Employee
1
1
View
Date Event Type Description Location Actions
2019-02-25 N/A Publication of Cowen Collaborative Insights report. N/A View

HOUSE_OVERSIGHT_024922.jpg

This document is page 106 of a report produced by Cowen, titled 'Collaborative Insights' and dated February 25, 2019. It is a directory page listing the addresses and phone numbers for Cowen's main U.S. locations (New York, Boston, Cleveland, San Francisco, Atlanta, Chicago, Stamford, Washington D.C.) and its international location in London. The document bears a 'HOUSE_OVERSIGHT_024922' Bates stamp, indicating it was part of a production to the House Oversight Committee, likely related to a broader investigation involving financial institutions.

Corporate report / contact directory page
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024921.jpg

This document is page 105 of a 'Cowen Collaborative Insights' report dated February 25, 2019. It serves as a 'Points of Contact' directory listing the profiles, contact information, and coverage areas for eleven Cowen research analysts. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024921', indicating it was produced during a House Oversight Committee investigation.

Corporate research report / contact list
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024920.jpg

This document is a financial chart produced by Cowen Collaborative Insights dated February 25, 2019. It details the rating history and stock performance of Canopy Growth Corporation from April 2016 to January 2019, including specific price targets. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella of Cowen.

Financial analysis report / stock rating history chart
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024919.jpg

This document is page 103 of a financial report produced by Cowen on February 25, 2019. It displays 'Rating History' charts for three companies: GW Pharmaceuticals Plc, Tilray, and Turning Point Brands, showing stock prices versus target prices over time (2016-2019). The document is marked with the Bates stamp 'HOUSE_OVERSIGHT_024919' and notes it is intended for Michael Cella at Cowen.

Financial analyst report / stock rating history
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024918.jpg

This document is a disclosure and disclaimer page from a Cowen Collaborative Insights equity research report dated February 25, 2019. It outlines Cowen's rating definitions (Outperform, Market Perform, Underperform), provides a statistical distribution of their ratings as of December 31, 2018, and lists legal notices for US, UK, and EU investors. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024918) and is watermarked for recipient Michael Cella.

Financial research report disclaimer / disclosure page
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024916.jpg

This document appears to be page 100 of a financial research report produced by Cowen Collaborative Insights, dated February 25, 2019. It details valuation methodologies and investment risks specifically related to the U.S. and Canadian cannabis industries. The page bears a House Oversight Committee Bates stamp, suggesting it was part of a larger production of documents, likely related to financial investigations, though the text itself does not mention Jeffrey Epstein.

Financial research report / disclaimer page
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024915.jpg

This document is page 99 of a report produced by Cowen Collaborative Insights, dated February 25, 2019. The content of the page is marked 'intentionally left blank,' though it includes a watermark restricting distribution to Michael Cella. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a document production for a congressional investigation.

Financial report page (intentionally blank)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024914.jpg

This is page 98 of a Cowen Collaborative Insights report dated February 25, 2019. It is a placeholder page marked 'This page left blank intentionally' containing a watermark for Michael Cella and a House Oversight Bates stamp (024914).

Corporate report (page from larger document)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024913.jpg

This document is page 97 of a report produced by Cowen Collaborative Insights, dated February 25, 2019. It is an intentionally blank placeholder page containing a watermark identifying Michael Cella as the intended recipient and a Bates stamp indicating it is part of a House Oversight Committee production (HOUSE_OVERSIGHT_024913).

Corporate report / financial research document (page 97)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024912.jpg

This document is page 96 of a financial research report titled 'Cowen Collaborative Insights' dated February 25, 2019. It contains 'Figure 136 Cannabis Comp Table,' an appendix listing market data and valuations for various cannabis-related companies such as Aphria Inc, Aurora Cannabis Inc, and Level Brands Inc. The document bears a 'HOUSE_OVERSIGHT_024912' stamp, indicating it was part of a document production to the House Oversight Committee, likely obtained from the files of Michael Cella at Cowen.

Financial research report (appendix)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024911.jpg

This document is page 95 of a financial research report by Cowen, dated February 25, 2019, analyzing the biodiesel market and biochemical CBD production methods. It details the economics of hemp biomass versus wood waste, provides data on biodiesel production inputs, and discusses Amyris's plans to produce CBD via sugarcane fermentation at their Brotas plant in Brazil following a $255 million agreement. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation.

Financial research report / industry analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024910.jpg

This document is page 94 of a Cowen Collaborative Insights research report dated February 25, 2019. It analyzes the industrial hemp market, detailing historical usage (specifically during WWII), current use cases (textiles, biofuels, food), and 2017 import statistics. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a larger congressional investigation (possibly related to Epstein's financial records or subpoenas), the content of this specific page is strictly agricultural and economic market research with no direct mention of Jeffrey Epstein.

Investment research report / market analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024909.jpg

Page 93 of a Cowen equity research report dated February 25, 2019. The text details clinical trial results for pharmaceutical companies GW and Zynerba regarding cannabinoid treatments (CBDV and ZYN002) for autism spectrum disorders, epilepsy, and Fragile X syndrome. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was included in a document production for a congressional investigation, though the specific page content is purely technical/medical market research.

Financial research report / equity research
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024908.jpg

This page is an excerpt from a Cowen equity research report dated February 25, 2019, analyzing GW Pharmaceuticals' clinical trials of CBD (Epidiolex/GWP42003) for schizophrenia and seizures (LGS). The text details positive statistical outcomes and safety profiles compared to placebos. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production (likely related to a subpoena of financial institutions), the content itself is purely medical and financial analysis and does not explicitly mention Jeffrey Epstein or his associates on this specific page.

Financial research report / equity research
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024907.jpg

This document is page 91 of a Cowen Collaborative Insights investment report dated February 25, 2019. It details the clinical trial results and investor analysis for the drug Epidiolex, specifically focusing on its efficacy in treating seizures (Dravet and LGS) with and without the concomitant use of clobazam, and noting that the drug is effective on its own. While part of a document production marked 'HOUSE_OVERSIGHT', the content is strictly pharmaceutical financial analysis and does not mention Jeffrey Epstein directly.

Investment research report / financial analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024906.jpg

This document is page 90 of a Cowen equity research report dated February 25, 2019, analyzing the clinical trial results (GWPCARE3) for GW Pharma's drug Epidiolex. It contains statistical data, bar charts, and a safety table regarding seizure reduction and adverse effects. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to the US House Oversight Committee, likely regarding financial records or communications involving the recipient or related parties.

Equity research report / financial analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024905.jpg

This document is page 89 of a Cowen Collaborative Insights research report dated February 25, 2019. It provides a detailed analysis of Phase 3 clinical trials for the drug Epidiolex (produced by GW Pharma) for the treatment of Lennox-Gastaut syndrome (LGS), including trial designs, efficacy statistics regarding seizure reduction, and adverse event data. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was collected as part of a congressional investigation.

Financial research report / equity research
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024904.jpg

A page from a Cowen research report dated February 25, 2019, analyzing the efficacy and safety of the drug Epidiolex by GW Pharma. It includes charts and tables detailing seizure reduction rates and adverse events in patients with Dravet Syndrome and Lennox-Gastaut Syndrome. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a document production to the US House Oversight Committee.

Financial research report / investment bank analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024903.jpg

This document is page 87 of a 'Cowen Collaborative Insights' report dated February 25, 2019, analyzing the pharmaceutical market for cannabinoid-based drugs, specifically focusing on GW Pharmaceuticals' Epidiolex and its clinical trials for epilepsy. The text details statistical results from Phase III trials, FDA approval timelines, and efficacy comparisons against placebos. The document bears a 'HOUSE_OVERSIGHT_024903' stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella at Cowen.

Financial/pharmaceutical research report (cowen collaborative insights)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024902.jpg

This document is page 86 of a Cowen 'Collaborative Insights' research report dated February 25, 2019, analyzing the cannabis market in Uruguay. It details corporate acquisitions of Uruguayan cannabis and hemp companies (ICC Labs, NettaGrowth, Inverell S.A.) by larger entities (Aurora, Khiron, Auxly) between 2016 and 2019. The document bears a House Oversight Bates stamp, indicating it was part of a document production for a congressional investigation.

Financial research report / market analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024901.jpg

This document is page 85 of a Cowen Collaborative Insights market research report dated February 25, 2019, analyzing the cannabis industry in Latin America. It details regulatory frameworks, market opportunities, and corporate activities (including JVs and licensing) for companies like Aurora, Khiron Life Sciences, and Pharamacielo in Colombia, Mexico, and Uruguay. The document bears a 'HOUSE_OVERSIGHT_024901' Bates stamp, indicating it was part of a document production for a US House Oversight Committee investigation.

Market research report / investment analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024900.jpg

This document is page 84 of a Cowen Collaborative Insights market research report dated February 25, 2019. It details the legal and business landscape of the medical cannabis industry in Chile and Colombia, listing various companies involved such as Dayacann, Tilray, and Canopy Growth. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was gathered as part of a congressional investigation, likely related to financial records or investment bank communications.

Investment research report / market analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024899.jpg

This page from a Cowen market research report, dated February 25, 2019, analyzes the regulatory environment and market trends for CBD and hemp products in Switzerland and France. It details Swiss regulations regarding cosmetic products and recent corporate consolidations (LGC Capital, Wayland, Creso Pharma), while noting France's status as a leading hemp cultivator despite strict government crackdowns on retail CBD sales. The document bears a House Oversight Committee stamp, suggesting it was part of a congressional document production.

Market research report / financial analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024898.jpg

This document is page 82 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing the cannabis and hemp markets in Italy and Switzerland. It details regulatory environments, specifically the 'cannabis light' market in Italy and medical/tobacco substitute regulations in Switzerland, while listing various corporate investments and acquisitions (Wayland, Canopy, CROP). The document bears a 'HOUSE_OVERSIGHT_024898' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely included in a larger batch of financial records.

Financial research report / market analysis
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024897.jpg

This document is page 81 of a Cowen Collaborative Insights market research report dated February 25, 2019, discussing the regulatory landscape for medical cannabis and CBD in Europe, specifically the UK and Italy. It details the legalization history, licensing requirements involving agencies like the MHRA and FSA, and market activities of companies like GW Pharmaceuticals, Tilray, Bedrocan, Canopy, and Aurora. The document bears a 'HOUSE_OVERSIGHT_024897' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.

Market research report / financial analysis
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
28
Total
28

Valuation Methodology and Risks

From: Cowen
To: Michael Cella

Investment report distribution restricted to michael.cella@cowen.com

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights Report

From: Cowen
To: Michael Cella

Analysis of Epidiolex drug trials and investor sentiment regarding efficacy with/without clobazam.

Report distribution
2019-02-25
Communication Source

Collaborative Insights

From: Cowen
To: Michael Cella

Financial analysis of cannabis and tobacco companies.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights - CBD Market Analysis

From: Cowen
To: Michael Cella

Market research report regarding CBD capsule pricing and demographic usage statistics.

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Market analysis of CBD gummy pricing and packaging.

Report distribution
2019-02-25
Communication Source

Report Distribution

From: Cowen
To: Michael Cella

This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited.

Report distribution
2019-02-25
Communication Source

Collaborative Insights

From: Cowen
To: Michael Cella

Financial report regarding cannabis market partnerships.

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Industry report on Synthetic Biology Cannabinoid Companies.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights

From: Cowen
To: Michael Cella

Market research report regarding hemp and CBD in textiles.

Report distribution
2019-02-25
Communication Source

Collaborative Insights - Topicals

From: Cowen
To: Michael Cella

Markey analysis of CBD topicals distributed to internal employee.

Report distribution
2019-02-25
Communication Source

Global CBD Landscape (Azer)

From: Cowen Collaborative In...
To: Michael Cella

Analysis of international drug conventions and WHO recommendations regarding CBD regulation.

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Industry analysis regarding CBD-infused textiles and partnerships.

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Financial rating history charts for GW Pharmaceuticals, Tilray, and Turning Point Brands.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights Report

From: Cowen
To: Michael Cella

Market analysis report regarding Uruguayan cannabis market.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights

From: Cowen
To: Michael Cella

Market research report on Cannabis/CBD in Switzerland and France

Report distribution
2019-02-25
Communication Source

Additional Applications / Implications - Epilepsy & Psych...

From: Cowen
To: Michael Cella

Analysis of cannabinoid-based drugs, specifically GW's Epidiolex and Zynerba's ZYN002, including clinical trial data.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights

From: Cowen Research
To: Michael Cella

Research report distribution intended for michael.cella@cowen.com

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Market analysis of corn, soybeans, and hemp production economics.

Report distribution
2019-02-25
Communication Source

Collaborative Insights

From: Cowen
To: Michael Cella

Financial report on Synthetic Biology and Cannabinoid production.

Report distribution
2019-02-25
Communication Source

Collaborative Insights

From: Cowen
To: Michael Cella

Financial report on Synthetic Biology and Cannabinoid production.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights

From: Cowen
To: Michael Cella

Research report regarding GW Pharma and Epidiolex efficacy/safety data.

Report distribution
2019-02-25
Communication Source

Collaborative Insights

From: Cowen
To: Michael Cella

Research report regarding GW Pharma and CBD clinical trials.

Report distribution
2019-02-25
Communication Source

Cowen Collaborative Insights

From: Cowen
To: Michael Cella

Market research report regarding CBD/Cannabis regulations in Europe.

Report distribution
2019-02-25
Communication Source

Consumer Products Market Sizing (Azer)

From: Cowen Collaborative In...
To: Michael Cella

Market research report regarding CBD usage statistics and market sizing.

Report distribution
2019-02-25
Communication Source

Collaborative Insights Report

From: Cowen
To: Michael Cella

Financial analysis of the U.S. Beauty and CBD Beauty markets.

Report distribution
2019-02-25
Communication Source

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search